What is claimed is:

1. A formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) a surfactant; wherein the molar ratio of surfactant to therapeutic protein is at least 100.

2. The formulation according to claim 1 wherein the molar ratio of surfactant to therapeutic protein is selected from the group consisting of at least 150, at least 200, at least 250, at least 300, at least 400, and at least 500.

3. The formulation according to claim 1 or 2 wherein the molar ratio of surfactant to therapeutic protein is about 545.

4. The formulation of any preceding claim wherein the surfactant is selected from the group consisting of polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80, polysorbate-85, poloxamer 88, and combinations thereof.

5. The formulation of any preceding claim wherein the formulation further comprises c) an antioxidant, wherein the molar ratio of antioxidant to therapeutic protein is at least 750.

6. The formulation of claim 5 wherein the molar ratio of antioxidant to therapeutic protein is selected from the group consisting of at least 5500, at least 6000, at least 6500, and at least 7000.

7. The formulation according to claim 5 or 6 wherein the molar ratio of antioxidant to therapeutic protein is about 7143.

8. The formulation according to any one of claims 5-7 wherein the antioxidant is selected from the group consisting of methionine, cysteine, glutathione, and monothioglycerol.

9. The formulation according to any preceding claim wherein the formulation further comprises d) a buffer, wherein the pH of the formulation is about 4.0 to about 8.0.

10. The formulation according to claim 10 wherein the buffer is selected from the group consisting of histidine, acetate, citrate, and succinate.

11. The formulation according to any preceding claim wherein the therapeutic protein is an antigen binding protein.

12. The formulation according to claim 11, wherein the antigen binding protein is an antibody or a fragment thereof.

13. The formulation according to claim 11 wherein the antigen binding protein is an immunoglobulin single variable domain.

14. The formulation according to claim 11 where the antigen binding protein binds to human CD3.

15. The formulation according to claim 14, wherein the antigen binding polypeptide is an anti-CD3 antibody.

16. The formulation according to claim 15, wherein the anti-CD3 antibody comprises a heavy chain comprising SEQ ID NO:1 and a light chain comprising SEQ ID NO:2.

17. The formulation according to any preceding claim wherein the therapeutic protein is present at a concentration of about 0.01 mg/ml to about 1 mg/ml.

18. The formulation according to any preceding claim wherein the therapeutic protein is present at a concentration of about 0.1 mg/ml to about 0.5 mg/ml.

19. The formulation according to any preceding claim wherein the therapeutic protein is present at a concentration of about 0.2 mg/ml.

20. The formulation according to any preceding claim wherein the formulation is a reconstituted formulation.

21. The formulation according to any preceding claim wherein the formulation is a liquid pharmaceutical formulation.

22. The formulation according to any preceding claim wherein the formulation is suitable for parenteral administration.

23. A formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) about 0.01% w/v to about 0.5% w/v surfactant, wherein the molar ratio of surfactant to therapeutic protein is at least 100; c) about 1 mM to about 50 mM antioxidant, wherein the molar ratio of antioxidant to therapeutic protein is at least 750; and d) about 1 mM to about 100 mM buffer, wherein the pH of the formulation is about 4.0 to about 8.0.

24. The formulation of claim 23 wherein the therapeutic protein is an antibody, wherein the surfactant is polysorbate 80, wherein the antioxidant is methionine, and wherein the buffer is histidine.

25. The formulation of claim 24 wherein the antibody is present at a concentration of about 0.2 mg/ml.

26. The formulation according to any preceding claim, wherein the formulation further comprises about 0.01 mM to about 1.0 mM EDTA.

27. The formulation according to claim 26, wherein the formulation comprises about 0.01 mM to about 0.1 mM EDTA.

28. The formulation according to claim 27, wherein the formulation comprises about 0.05 mM EDTA.

What is claimed is:

1. A formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) a surfactant; wherein the molar ratio of surfactant to therapeutic protein is at least 100.

2. The formulation according to claim 1 wherein the molar ratio of surfactant to therapeutic protein is selected from the group consisting of at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, and about 545.

3. The formulation of any preceding claim wherein the surfactant is selected from the group consisting of polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80, polysorbate-85, poloxamer 88, and combinations thereof.

4. The formulation of any preceding claim wherein the formulation further comprises c) an antioxidant, wherein the molar ratio of antioxidant to therapeutic protein is at least 750.

5. The formulation of claim 4 wherein the molar ratio of antioxidant to therapeutic protein is selected from the group consisting of at least 5500, at least 6000, at least 6500, at least 7000, and about 7143.

6. The formulation according to claim 4 or claim 5 wherein the antioxidant is selected from the group consisting of methionine, cysteine, glutathione, and monothioglycerol.

7. The formulation according to any preceding claim wherein the formulation further comprises d) a buffer, wherein the pH of the formulation is 4.0 to 8.0.

8. The formulation according to claim 7 wherein the buffer is selected from the group consisting of histidine, acetate, citrate, and succinate.

9. The formulation according to any preceding claim wherein the therapeutic protein is an antigen binding protein.

10. The formulation according to claim 9, wherein the antigen binding protein is selected from the group consisting of an antibody or a fragment thereof, an immunoglobulin single variable domain, an anti-CD3 antibody, and the anti-CD3 antibody comprises a heavy chain comprising SEQ ID NO:1 and a light chain comprising SEQ ID NO:2.

11. The formulation according to any preceding claim wherein the therapeutic protein is present at a concentration of 0.01 mg/ml to 1 mg/ml, 0.1 mg/ml to 0.5 mg/ml, or 0.2 mg/ml.

12. The formulation according to any preceding claim wherein the formulation is a reconstituted formulation and/or a liquid pharmaceutical formulation, and/or wherein the formulation is suitable for parenteral administration.

13. A formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) 0.01% w/v to 0.5% w/v surfactant, wherein the molar ratio of surfactant to therapeutic protein is at least 100; c) 1 mM to 50 mM antioxidant, wherein the molar ratio of antioxidant to therapeutic protein is at least 750; and d) 1 mM to 100 mM buffer, wherein the pH of the formulation is 4.0 to 8.0.

14. The formulation of claim 13 wherein the therapeutic protein is an antibody, wherein the surfactant is polysorbate 80, wherein the antioxidant is methionine, and wherein the buffer is histidine.

15. The formulation according to any preceding claim, wherein the formulation further comprises 0.01 mM to 1.0 mM EDTA, 0.01 mM to 0.1 mM EDTA, or 0.05 mM EDTA.